Navigation Links
deCODE Receives Nasdaq Bid Price Deficiency Notice
Date:9/17/2009

REYKJAVIK, Iceland, September 17 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced that it has received a notice from the Nasdaq Stock Market indicating that deCODE is not in compliance with Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule") because the closing bid price per share for its common stock has been below $1.00 per share for 30 consecutive business days. In accordance with Nasdaq Listing Rules, deCODE will be provided 180 calendar days, or until March 15, 2010, to regain compliance with the Minimum Bid Price Rule. deCODE can achieve compliance if at any time before March 15, 2010, its common stock closes at $1.00 per share or more for at least 10 consecutive business days. This notification has no effect on the listing of deCODE's common stock at this time.

About deCODE

deCODE is a global leader in analysing and understanding the human genome. The company has identified key variations in the sequence of the genome conferring increased risk of major public health challenges from cardiovascular disease to cancer, and employs its gene discovery engine to develop DNA-based tests and scans to assess individual risk of common diseases; to license its tests and intellectual property to partners; and to provide comprehensive, leading- edge contract services to companies and research institutions around the globe. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at http://www.decode.com; at http://www.decodediagnostics.com; at http://www.decodeme.com; and on our blog at http://www.decodeyou.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the effect of a potential delisting of our common stock from The Nasdaq Global Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

    Contacts:

    deCODE genetics
    Joy Bessenger
    +1-212-481 3891
    ir@decode.is

    Edward Farmer
    +354-570-1900
    info@decode.is

    Gisli Arnason
    +354-570-1900
    info@decode.is



'/>"/>
SOURCE DeCODE Genetics Inc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE genetics Announces Second Quarter 2009 Financial Results
2. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results
3. Its Not Just the Sun: deCODE Discovers Sequence Variants Affecting Susceptibility to Skin Cancer
4. deCODE Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis
5. deCODE Reinstated to Nasdaq Global Market
6. deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation
7. deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease
8. deCODE genetics Announces First Quarter 2009 Financial Results
9. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2009 Financial Results
10. Nasdaq Stays Suspension of Trading in deCODE Stock
11. deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court of New ... the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company (DPCL) for ... one of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary Dishman USA ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today announced ... allow more customers to receive their primers in a ... compromise in quality found with other providers. Express oligos ... States at no additional fee. ... genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, and ...
(Date:1/13/2017)... Jan 13, 2017 Research and Markets has ... Application - Global Forecast to 2021" report to their offering. ... The biosimilars ... USD 3.39 Billion in 2016, at a CAGR of 26.3%. ... of product, manufacturing type, and application. Factors such as rising incidence ...
(Date:1/13/2017)... , ... January 13, 2017 , ... ... cuvette-related demand that it has found among its diverse customer base. The latest ... use in most brands electroporators including BTX and Bio-Rad. FireflySci is introducing three ...
Breaking Biology Technology:
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CES® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/19/2016)... , España y TORONTO , 19 de ... con Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, ... clínicos en varios tipos de tumor en 2017, con múltiples sitios ... ... su clase con objetivo en el factor inhibidor de leucemia (LIF), ...
Breaking Biology News(10 mins):